Combination therapy reduced HER2-positive breast cancers

	Tweet

A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. Full results were presented at the symposium during a press briefing on Dec. 10, 2010, at 8:00 a.m. CT.

Reporters who cannot attend in person can participate using the following call-in information:

* U.S. and Canada: (888) 282-7404
* International: (706) 679-5207
* Access Code: 25346432

Lead researcher José Baselga, M.D., Ph.D., chief of the division of hematology and oncology and associate director of the Massachusetts General Hospital Cancer Center, said early data indicate a 50 percent rate of pathological complete remission compared with 20 percent for either agent alone. 

"This study suggests that a dual blockade against HER2 is an efficient way to target HER2-positive breast tumors and that lapatinib adds to trastuzumab. While further research is ongoing, our results indicate that we are on the right track to improve the therapy of HER2-positive disease,” said Baselga, who is also a founding editor-in-chief of the AACR’s newest journal Cancer Discovery, along with Lewis C. Cantley, Ph.D.

These results are from the NeoALTTO Trial, an international, multicenter, randomized study comparing the efficacy of lapatinib plus paclitaxel vs. trastuzumab plus paclitaxel vs. a combination of all three agents as neoadjuvant chemotherapy among 455 patients with HER2-positive breast cancer.

“It has been suggested in basic science research and smaller clinical trials that the combination of these therapies would be more effective than either alone, but this is the first time it has been shown in a large clinical trial setting,” said Baselga.

At the symposium, Baselga presented the primary outcome of tumor rate after surgery, as well as the secondary outcomes of objective response rate, safety, pathologic node-negative status, rate of conversion to breast conservation, disease free survival and overall survival.

###

Follow the AACR on Twitter @AACR, and throughout the meeting using the hash tag #SABCS.

Recordings of the teleconferences and video interviews with researchers will posted to the AACR website throughout the meeting: http://www.aacr.org/page23506.aspx.

The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor, and the AACR’s scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 33rd annual symposium is expected to draw nearly 9,000 participants from more than 90 countries.

###

Contact: Jeremy Moore

267-646-0557
American Association for Cancer Research

RELATED STORIES:
Experimental Agent Reduces Breast Cancer Metastasis to Bone   Late treatment with letrozole can reduce breast cancer recurrence risk   Male breast cancer worse for blacks than whites   Extracts of catfish caught in polluted waters cause breast cancer cells to multiply   Breast Cancer Patients with BRCA Mutations at 4x Higher Risk for Contralateral Breast Cancer   Smoking Increases Breast Cancer Risk Based on Genes   New target identified to stop the spread of breast cancer   Mammograms May Detect Some Cancers That Would Have Regressed   New Test Found for Effectiveness of Baking Soda as Breast Cancer Therapy   UT Southwestern launches clinical trial for treatment of breast cancer using CyberKnife   Herceptin Tied to Heart Issues in Breast Cancer   Alcohol may raise chances of breast cancer return   Acupuncture reduces side effects of breast cancer treatment as much as conventional drug therapy   Women not following through with recommended breast screening MRI   Partners of breast cancer patients are at risk of developing mood disorders   Menopause drug Livial ups breast cancer return risk   Seven quality guidelines for breast, colorectal cancer care   Fewer than half of breast cancer patients adhere to hormonal therapy regimen, study finds   Alcohol may influence breast cancer recurrence   Waiting for biopsy results may adversely affect health   Being too fat raises risk of deadly breast cancer: study   Breastfeeding for a year cuts cancer risk by a third: Study

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]